SCHEMBL348012

SCHEMBL348012

COC(=O)Cc1cc(Cl)cc(OCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.52
LMNA P02545 1/20 0.49
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
LTB4R Q15722 2/20 0.47
LTB4R2 Q9NPC1 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSP90AB1 P08238 1/20 0.46
RXRA P19793 2/20 0.46
RXRB P28702 2/20 0.46
RXRG P48443 2/20 0.46
MAOB P27338 4/20 0.45
NR4A2 P43354 1/20 0.45
MAOA P21397 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490786 0.90 MEN1 (0.59) LMNANPC1RAB9AALDH1A1MEN1
SCHEMBL9204780 0.90 LTB4R (0.55) LMNANPC1RAB9AALDH1A1MEN1
SCHEMBL137417 0.87 MAOB (0.54) MRGPRX4LMNAALDH1A1MEN1KMT2A
SCHEMBL1592618 0.86 HSP90AB1 (0.61) LMNANPC1RAB9AALDH1A1MEN1
SCHEMBL135152 0.86 LTB4R (0.57) MRGPRX4MEN1KMT2ALTB4RLTB4R2
SCHEMBL11891941 0.85 MEN1 (0.50) LMNANPC1RAB9AALDH1A1MEN1
SCHEMBL12703271 0.85 LTB4R (0.56) MRGPRX4NPC1RAB9AALDH1A1MEN1
SCHEMBL10077742 0.84 PPARG (0.53) MRGPRX4NPC1RAB9AALDH1A1MEN1
SCHEMBL2968381 0.84 MEN1 (0.49) MRGPRX4LMNANPC1RAB9AALDH1A1
SCHEMBL2848161 0.83 MAOB (0.60) MRGPRX4RAB9AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247602-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-21 US disclosed
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2012-01-19 US disclosed
US-8071807-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2011-12-06 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-06-16 US disclosed
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 MRGPRX4 107/4885LMNA 2277/4885NPC1 3229/4885
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 MRGPRX4 107/4885LMNA 2277/4885NPC1 3229/4885
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 MRGPRX4 107/4885LMNA 2277/4885NPC1 3229/4885
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 MRGPRX4 98/4885LMNA 2161/4885NPC1 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.